Stock Chart
AZTA
This target is derived from long-term trendline analysis and projected growth.
Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.
Target may adjust dynamically as the stock trend reverses or accelerates.
Type: SELL growth_1yr
Strike: $40
Premium: $8.20
Expiry: Dec 18, 2026
Target: $36
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.
How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future
Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling
⚠️ Not a prediction. Shows trend projection only.
R-squared: 0.72
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About AZTA - Azenta, Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample …
Key Statistics
More AZTA Analysis
This AZTA stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track AZTA's price movements with trendlines, gamma walls, and key support/resistance levels.